Cytokine-Driven Immunopathogenesis of Psoriasis: Clinical Therapeutic Targets and Future Immunologic Directions
International Journal of Pharmaceutical and Healthcare Innovation · 27.04.2026 · 3 (3) · 903-923
DOI: 10.62752/ijphi.v3i2.243 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical and Healthcare Innovation, online erschienen am 27.04.2026. Verfasst von Akanksha und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Psoriasis is a chronic inflammatory skin disorder affecting ~2% of the global population, characterized by erythematous, scaly plaques. It involves a complex interplay of immune dysregulation and genetic susceptibility. Pathogenesis: The disease is driven by persistent activation of immune cells and overproduction of pro-inflammatory cytokines. Genome-wide association studies have identified polymorphisms in genes encoding cytokines, their receptors, and signalling molecules, highlighting their central role. Elevated serum cytokine levels and their overexpression in psoriatic lesions correlate with disease severity. Immunological Insights: Initially considered a type-1 immune-mediated disorder due to the involvement of cytokines such as interferon-γ, interleukin-2 (IL-2), and interleukin-12 (IL-12), psoriasis understanding has evolved significantly. The discovery of T helper 17 cells (Th17 cells) and their associated cytokines has redefined its immunopathology and provided new therapeutic targets. Contributing Factors: Psoriasis develops in genetically predisposed individuals through interactions between environmental triggers and immune responses. Therapeutic Advances: Targeted cytokine-based therapies, including biologics, have improved disease management by specifically modulating key inflammatory pathways.
Conclusion
Cytokine dysregulation is central to psoriasis pathogenesis, and continued exploration of cytokine networks offers promising avenues for more effective and personalized treatments.
Zitieren
APA
Akanksha, Gupta, R. K., Keshari, A. K., & Singh, S. P. (2026). Cytokine-Driven Immunopathogenesis of Psoriasis: Clinical Therapeutic Targets and Future Immunologic Directions. International Journal of Pharmaceutical and Healthcare Innovation, 3(3), 903-923. https://doi.org/10.62752/ijphi.v3i2.243
Vancouver
Akanksha, Gupta RK, Keshari AK, Singh SP. Cytokine-Driven Immunopathogenesis of Psoriasis: Clinical Therapeutic Targets and Future Immunologic Directions. International Journal of Pharmaceutical and Healthcare Innovation. 2026;3(3):903-923. doi:10.62752/ijphi.v3i2.243
BibTeX
@article{Akanksha2026,
author = {Akanksha and Gupta, Ramesh Kr and Keshari, Amit K and Singh, Satya Prakash},
title = {Cytokine-Driven Immunopathogenesis of Psoriasis: Clinical Therapeutic Targets and Future Immunologic Directions},
journal = {International Journal of Pharmaceutical and Healthcare Innovation},
year = {2026},
volume = {3},
number = {3},
pages = {903--923},
doi = {10.62752/ijphi.v3i2.243}
}
EUVIMED